123 related articles for article (PubMed ID: 21612753)
1. Fabry disease: results of the first UK hemodialysis screening study.
Wallin EF; Clatworthy MR; Pritchard NR
Clin Nephrol; 2011 Jun; 75(6):506-10. PubMed ID: 21612753
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
3. Significance of screening for Fabry disease among male dialysis patients.
Ichinose M; Nakayama M; Ohashi T; Utsunomiya Y; Kobayashi M; Eto Y
Clin Exp Nephrol; 2005 Sep; 9(3):228-32. PubMed ID: 16189631
[TBL] [Abstract][Full Text] [Related]
4. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test.
Andrade J; Waters PJ; Singh RS; Levin A; Toh BC; Vallance HD; Sirrs S
Clin J Am Soc Nephrol; 2008 Jan; 3(1):139-45. PubMed ID: 18003767
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province.
Sayilar EI; Ayar Y; Yavuz M
Clin Nephrol; 2016 Mar; 85(3):165-72. PubMed ID: 26833297
[TBL] [Abstract][Full Text] [Related]
6. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
Sadasivan C; Chow JTY; Sheng B; Chan DKH; Fan Y; Choi PCL; Wong JKT; Tong MMB; Chan TN; Fung E; Kam KKH; Chan JYS; Chi WK; Paterson DI; Senaratne M; Brass N; Oudit GY; Lee APW
PLoS One; 2020; 15(9):e0239675. PubMed ID: 32987398
[TBL] [Abstract][Full Text] [Related]
7. Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center.
Lin CJ; Chien YH; Lai TS; Shih HM; Chen YC; Pan CF; Chen HH; Hwu WL; Wu CJ
Kidney Blood Press Res; 2018; 43(5):1636-1645. PubMed ID: 30380558
[TBL] [Abstract][Full Text] [Related]
8. Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening.
Silva CA; Barreto FC; Dos Reis MA; Moura Junior JA; Cruz CM
Nephron; 2016; 134(4):221-230. PubMed ID: 27576502
[TBL] [Abstract][Full Text] [Related]
9. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.
Okur I; Ezgu F; Biberoglu G; Tumer L; Erten Y; Isitman M; Eminoglu FT; Hasanoglu A
Gene; 2013 Sep; 527(1):42-7. PubMed ID: 23756194
[TBL] [Abstract][Full Text] [Related]
10. Screening for Fabry disease among 619 hemodialysis patients in Saudi Arabia.
Alhemyadi SA; Elawad M; Fourtounas K; Abdrabbou Z; Alaraki B; Younis S; Nawaz Z; Alqurashi S; Mohamed S
Saudi Med J; 2020 Aug; 41(8):813-818. PubMed ID: 32789421
[TBL] [Abstract][Full Text] [Related]
11. Alpha-galactosidase A activity levels in Turkish male hemodialysis patients.
Kalkan Uçar S; Sozmen E; Duman S; Başçi A; Çoker M
Ther Apher Dial; 2012 Dec; 16(6):560-5. PubMed ID: 23190516
[TBL] [Abstract][Full Text] [Related]
12. [Fabry disease: enzymatic screening using dried blood spots on filter paper].
Caudron E; Germain DP; Prognon P
Rev Med Interne; 2010 Dec; 31 Suppl 2():S263-9. PubMed ID: 21211677
[TBL] [Abstract][Full Text] [Related]
13. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.
Tanaka M; Ohashi T; Kobayashi M; Eto Y; Miyamura N; Nishida K; Araki E; Itoh K; Matsushita K; Hara M; Kuwahara K; Nakano T; Yasumoto N; Nonoguchi H; Tomita K
Clin Nephrol; 2005 Oct; 64(4):281-7. PubMed ID: 16240899
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report.
Porsch DB; Nunes AC; Milani V; Rossato LB; Mattos CB; Tsao M; Netto C; Burin M; Pereira F; Matte U; Giugliani R; Barros EJ
Ren Fail; 2008; 30(9):825-30. PubMed ID: 18925518
[TBL] [Abstract][Full Text] [Related]
15. Cost Efficacy of α-Galactosidase A Enzyme Screening for Fabry Disease.
Newman DB; Miranda WR; Matern D; Peck DS; Geske JB; Maleszewski JJ; Ommen SR; Ackerman MJ
Mayo Clin Proc; 2019 Jan; 94(1):84-88. PubMed ID: 30611458
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD study.
Jahan S; Sarathchandran S; Akhter S; Goldblatt J; Stark S; Crawford D; Mallett A; Thomas M
Orphanet J Rare Dis; 2020 Jan; 15(1):10. PubMed ID: 31931840
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: An alternative methodology.
Caudron E; Prognon P; Germain DP
Eur J Med Genet; 2015 Dec; 58(12):681-4. PubMed ID: 26520229
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease: a new approach for the screening of females in high-risk groups.
Pasqualim G; Simon L; Sperb-Ludwig F; Burin MG; Michelin-Tirelli K; Giugliani R; Matte U
Clin Biochem; 2014 May; 47(7-8):657-62. PubMed ID: 24582695
[TBL] [Abstract][Full Text] [Related]
19. Case report: is low α-Gal enzyme activity sufficient to establish the diagnosis of Fabry disease?
Biagini G; Almeida ACSF; Almeida TVR; Silva CAB; Castro BF; Reche TC; Dabinski AC; Barreto FC
J Bras Nefrol; 2017; 39(3):333-336. PubMed ID: 29044343
[TBL] [Abstract][Full Text] [Related]
20. α-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females.
Baydakova GV; Ilyushkina AA; Moiseev S; Bychkov IO; Nikitina NV; Buruleva ТА; Zakharova EY
Clin Chim Acta; 2020 Feb; 501():27-32. PubMed ID: 31770509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
